Treatment of very elderly glioblastoma patients ≥ 75 years of age: whom to treat

Purpose The prognosis of patients ≥ 75 years suffering from glioblastoma is poor. Novel therapies are usually reserved for patients ≤ 70 years. In an aging population, treatment of very elderly patients remains a challenge. Methods Between 2010 and 2018, a total of 977 glioblastoma patients were tre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2023-12, Vol.165 (3), p.509-515
Hauptverfasser: Baumgarten, Peter, Prange, Georg, Kamp, Marcel A., Monden, Daniel, Neef, Vanessa, Schwarzer, Franziska, Dubinski, Daniel, Dinc, Nazife, Weber, Katharina J., Czabanka, Markus, Hattingen, Elke, Ronellenfitsch, Michael W., Steinbach, Joachim P., Senft, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose The prognosis of patients ≥ 75 years suffering from glioblastoma is poor. Novel therapies are usually reserved for patients ≤ 70 years. In an aging population, treatment of very elderly patients remains a challenge. Methods Between 2010 and 2018, a total of 977 glioblastoma patients were treated at our institution. Of these, 143 patients were ≥ 75 years at diagnosis. Primary procedure was surgical resection or biopsy followed by adjuvant treatment, whenever possible. We retrospectively investigated overall survival (OS) and potential prognostic factors influencing survival, including Karnofsky Performance Status (KPS), surgical therapy, adjuvant therapy as well as MGMT promotor status. Results In very elderly patients, median age was 79 years (range: 75–110). Biopsy only was performed in 104 patients; resection was performed in 39 patients. Median OS for the entire cohort was 5.9 months. Univariate analysis showed that KPS at presentation (≥ 70 vs. ≤60), surgery vs. biopsy, adjuvant chemotherapy and adjuvant radiotherapy were significantly associated with OS (6 vs. 3, p 
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-023-04518-w